Mibefradil

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Mibefradil
Mibefradil.svg
Clinical data
Trade namesPosicor
AHFS/Drugs.comMicromedex Detailed Consumer Information
MedlinePlusa607007
Routes of
administration
By mouth (tablets)
ATC code
Legal status
Legal status
  • Withdrawn from market
Pharmacokinetic data
Bioavailability70%
Protein binding>99%
MetabolismLiver
Elimination half-life17–25 hours
Identifiers
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
PDB ligand
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC29H38FN3O3
Molar mass495.63 g/mol g·mol−1
3D model (JSmol)
Melting point128 °C (262 °F) (dihydrochloride salt)
 ☒N☑Y (what is this?)  (verify)

Mibefradil (Posicor) is a drug used for the treatment of hypertension and chronic angina pectoris. It is a nonselective calcium channel blocker.[1]

The mechanism of action of mibefradil is characterized by the selective blockade of transient, low-voltage-activated (T-type) calcium channels over long-lasting, high-voltage-activated (L-type) calcium channels, which is probably responsible for many of its unique properties.

On June 8, 1998, Roche announced the voluntary withdrawal of the drug from the market, one year after approval by the FDA, due to the potential for drug interactions, some of them deadly, which may occur when it is taken together with some other medications.[2]

Synthesis[edit]

Mibefradil synthesis: YU 22988  ZW 20087 

References[edit]

  1. ^ Bezprozvanny I, Tsien RW (September 1995). "Voltage-dependent blockade of diverse types of voltage-gated Ca2+ channels expressed in Xenopus oocytes by the Ca2+ channel antagonist mibefradil (Ro 40-5967)". Mol. Pharmacol. 48 (3): 540–9. PMID 7565636.
  2. ^ Stolberg, Sheryl Gay (1998-06-09). "Heart Drug Withdrawn as Evidence Shows It Could Be Lethal". The New York Times. Retrieved 2019-01-12.